New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:35 EDTPETXAratana Therapeutics initiates pivotal study for AT-001
Aratana Therapeutics announced the initiation of the pivotal field effectiveness study for AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis. The randomized, blinded, multicenter pivotal study will enroll approximately 300 client-owned dogs with osteoarthritis, and will be conducted under a study protocol for which Aratana received concurrence from the FDA's Center for Veterinary Medicine. The primary endpoint will be a reduction in osteoarthritis pain compared to placebo, as indicated by the Canine Brief Pain Inventory scale, a well validated and widely used scoring system.
News For PETX From The Last 14 Days
Check below for free stories on PETX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
09:22 EDTPETXAratana Therapeutics 4.5M share Spot Secondary priced at $9.25
Subscribe for More Information
September 16, 2014
18:30 EDTPETXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Apogee Enterprises (APOG), up 5.6% after reporting second quarter results and raising fiscal 2015 guidance. ALSO HIGHER: InspireMD (NSPR), up 18.5% after reporting positive trial results for CGuard... Boeing (BA), up marginally after NASA awarded the company with a $4.2B contract for commercial spaceflight to the International Space Station... U.S. Steel (X), up 7.9%% after updating third quarter outlook. DOWN AFTER EARNINGS: Adobe (ADBE), down 4.5% following third quarter results. ALSO LOWER: Rackspace Hosting (RAX), down 16.7% after ending strategic review and deciding to stay independent... Sunoco Logistics Partners (SXL), down 3.9% after filing to sell 7.7M shares of common stock... Aratana Therapeutics (PETX), down 7.8% after filing to sell common stock.
16:01 EDTPETXAratana Therapeutics files to sell common stock, no amount given
Subscribe for More Information
September 9, 2014
07:05 EDTPETXAratana Therapeutics announces positive results from AT-003 field study
Aratana Therapeutics announced positive results from its pilot field study of its Bupivacaine Extended-Release Injectable Suspension, or AT-003, for managing post-operative pain in cats and dogs following surgery. In the study, which enrolled 46 client-owned dogs, AT-003 demonstrated significantly greater pain control over time following knee surgery compared to placebo. Based on these results, Aratana anticipates discussing the design of the pivotal field effectiveness with the FDA in the coming weeks and continues to anticipate the first FDA approval in 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use